Ocular Therapeutix, Inc. OCUL
As ofNov 20, 2026, 3:36 PM EST
- YTD
- -54.10%
- 1 year
- -52.45%
5D -0.38 (-6.14%)
- Market cap
- 1.22B
- Revenue (ttm)
- 50.38M
- EPS (ttm)
- -1.44
- Shares out
- 220.02M
- Forward P/E
- -3.68
- YTD return
- -54.10%
- 1-year return
- -52.45%
- 50-day average
- 7.68
- 200-day average
- 8.86
- Enterprise value
- 856.34M
- Volume
- 1.76M
- Avg volume
- 3.03M
- Open
- 5.76
- Previous close
- 5.86
- Day's range
- 5.56 – 5.95
- 52-week range
- 5.56 – 16.11
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 25.73 (+361.7%)
- Earnings date
- Feb 4, 2027
Key statistics
- Price / sales
- 25.59
- Price / book
- 2.92
- Revenue growth
- -11.50%
- Free cash flow
- -159.98M
- Total cash
- 530.61M
- Total debt
- 80.01M
- Return on equity
- -93.48%
- Short % of float
- 15.56%
Fundamental scorecard
5 of 25 checks passed on OCUL’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 14.00
- Target (mean)
- 25.73
- Target (high)
- 34.00
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate -0.3548.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | -0.45 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.36348 | -0.42 | -0.06 | -15.55% |
| Aug 3, 2026 | Jun 30, 2026 | -0.39545 | -0.35 | +0.05 | +11.49% |
| May 5, 2026 | Mar 31, 2026 | -0.32 | -0.41 | -0.09 | -28.12% |
| Feb 5, 2026 | Dec 31, 2025 | -0.33 | -0.29 | +0.04 | +12.12% |
| Nov 4, 2025 | Sep 30, 2025 | -0.39 | -0.37 | +0.02 | +5.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 19, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 2, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 29, 2026 | Needham | reit | Buy | Buy |
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ocutx.com
News
Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $28 Price Target
Ocular: Maintaining 'Buy' On AXPAXLI NDA Submission Q4 2026 And DR Expansion Possibility HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28
Ocular Therapeutix Q3 2026 Earnings Call Transcript Ocular Therapeutix Q3 EPS $(0.42) Misses $(0.36) Estimate, Sales $12.874M Miss $14.339M Estimate
Your note
Sign in to keep a note on OCUL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERMAN TODD | Officer | Sale | Oct 7, 2026 | 140,484 |
| DUGEL PRAVIN U | Chief Executive Officer | Stock Gift | Aug 24, 2026 | 0 |
| HEIER JEFFREY S. | Officer | Sale | Oct 1, 2026 | 307,457 |
| KAISER PETER KAZUO | Officer | Sale | Oct 1, 2026 | 254,388 |
| LINDSTROM RICHARD L | Director | Stock Award(Grant) | Jun 9, 2026 | 260,933 |
| MEYERS STEVE LAWRENCE | Officer | Stock Award(Grant) | Jan 1, 2026 | 217,628 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.07% | 33,160,034 | 194.32M | Sep 29, 2026 |
| Deep Track Capital, Lp | 9.97% | 21,939,625 | 128.57M | Sep 29, 2026 |
| Blackrock Inc. | 9.08% | 19,974,781 | 117.05M | Sep 29, 2026 |
| Summer Road LLC | 5.66% | 12,463,296 | 73.03M | Sep 29, 2026 |
| Avoro Capital Advisors LLC | 5.63% | 12,380,300 | 72.55M | Sep 29, 2026 |
| Venrock Adviser, LLC | 4.70% | 10,346,926 | 60.63M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.46% | 9,804,363 | 57.45M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 6,616,995 | 38.78M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.53% | 5,562,722 | 32.60M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.25% | 2,751,674 | 16.12M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.12% | 2,461,078 | 14.42M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 2,261,254 | 13.25M | Aug 30, 2026 |
